enVVeno Medical Corporation (NVNO)

NCM – Цена в реальном времени. Валюта: USD

10.84

-0.21 (-1.90%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

10.84

0.00 (0.00%)

После закрытия: Jun 26, 2026, 4:10 PM EDT

02.06.2026

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ET Register here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Virtual Investor Closing Bell event on Tuesday, June 9, 2026 at 4:00 PM ET. As part of the event, Mr.

12.05.2026

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve IDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3 million U.S. patients suffering from DVI Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / May 12, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr.

07.05.2026

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

Company ended the first quarter with approximately $25 million in cash and investments Capital on hand should fund operations through multiple key milestones into Q3 2027 Company recently received FDA IDE approval to commence TAVVE U.S. Pivotal Study for non-surgical replacement venous valve, enVVe System TAVVE site selection is underway with patient enrollment expected to commence later this year IRVINE, CA / ACCESS Newswire / May 7, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the first quarter 2026, ending the quarter with approximately $25 million in cash and investments and confirming the Company's strategic focus on the development of its next-generation enVVe® System for the treatment of deep venous insufficiency. "With a strong balance sheet, significant physician interest in the enVVe valve, and a clearly defined regulatory pathway, we are well positioned to execute the TAVVE study and advance the Company towards multiple near-term and long-term milestones," said Robert Berman, Chief Executive Officer of enVVeno Medical.

29.04.2026

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial Clinical site activation and patient enrollment expected to commence later this year Large unmet clinical need for approximately 3 million U.S. patients with severe deep Chronic Venous Insufficiency Potential multi-billion-dollar untapped U.S. market Company has approximately $25 million in cash and investments to fund operations into Q3 2027 IRVINE, CA / ACCESS Newswire / April 29, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that the U.S. Food and Drug Administration (FDA) has awarded the Company the first-ever IDE approval to proceed with a U.S. pivotal study of a non-surgical replacement venous valve. The Transcatheter Venous Valve Endoprosthesis (TAVVE®) pivotal study will evaluate the Company's minimally invasive enVVe® System for patients with severe deep Chronic Venous Insufficiency (CVI).

27.03.2026

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

Company accelerated development of the enVVe® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiation Strong financial position expected to provide an operating runway into mid-2027 through the achievement of key clinical milestones IRVINE, CA / ACCESS Newswire / March 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced financial results for the year ended December 31, 2025 and provided a corporate update highlighting its strategic focus on the development of its next-generation enVVe® System. Robert Berman, Chief Executive Officer of enVVeno Medical Corporation, stated, "2025 represented a significant inflection point for the Company.

03.03.2026

NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives

NEWPORT BEACH, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund II”), a subsidiary of NorthStrive Companies Inc., headquartered in Newport Beach, California, and beneficial owner of approximately 5.05% of the outstanding common stock of enVVeno Medical Corporation (“enVVeno” or the “Company”), today issued the following open letter to the Company's Board of Directors (the “Board”) and fellow shareholders:

04.02.2026

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed Reports Cash and Investments of approximately $28 million as of the Year Ended December 31, 2025 IRVINE, CA / ACCESS Newswire / February 4, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed that for the last 10 consecutive business days, from January 20, 2026 through February 2, 2026, the closing bid price of the Company's common stock was at or above $1.00, and as a result, the matter is now closed.

Видео

No Data

There is no data to display

Пресс-релизы

02.06.2026

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

12.05.2026

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

07.05.2026

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

29.04.2026

enVVeno Medical Corporation (NVNO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

enVVeno Medical Corporation (NVNO)

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Видео

No Data

Пресс-релизы

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Видео

No Data

Пресс-релизы

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

Search stocks

enVVeno Medical Corporation (NVNO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

enVVeno Medical Corporation (NVNO)

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Видео

No Data

Пресс-релизы

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Видео

No Data

Пресс-релизы

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve